Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have earned an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $110.9091.

GPCR has been the subject of several recent analyst reports. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a research note on Friday, August 7th. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 17th. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research note on Friday, August 7th. HC Wainwright decreased their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Thursday, June 11th. Finally, Citizens Jmp decreased their price objective on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research note on Friday, August 7th.

Hedge Funds Weigh In On Structure Therapeutics

Several hedge funds have recently added to or reduced their stakes in GPCR. Morgan Stanley lifted its position in shares of Structure Therapeutics by 261.4% during the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after buying an additional 1,510,093 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after buying an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Structure Therapeutics by 477.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after buying an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Structure Therapeutics by 21.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC acquired a new position in Structure Therapeutics in the 4th quarter valued at about $61,086,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

NASDAQ GPCR opened at $45.91 on Tuesday. The stock’s fifty day moving average is $50.81 and its two-hundred day moving average is $50.07. The firm has a market capitalization of $3.20 billion, a P/E ratio of -45.91 and a beta of -1.43. Structure Therapeutics has a fifty-two week low of $18.26 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, sell-side analysts forecast that Structure Therapeutics will post -1.84 EPS for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.